PPMD's Blog – October 2012 Archive (3)
Today's (October 31st) MD STARnet Webinar Postponed due to Hurricane
Dear Friends,
Due to the recent hurricane we are going to postpone tomorrow's MD STARnet webinar.
We will be in touch regarding the new date. Sorry for the inconvenience.
Best,
Ryan Fischer
PPMD
EVENT DETAILS…
Added by PPMD on October 30, 2012 at 1:00pm — No Comments
Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy
New release from Prosensa:
£10m in milestone payments received from GlaxoSmithKline
Leiden, The Netherlands, 23 October 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted…
ContinueAdded by PPMD on October 23, 2012 at 12:35pm — 2 Comments
Full 48-week Phase IIb data from eteplirsen study in Duchenne presented at World Muscle Society
Dr. Jerry Mendell, Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investigator of the Phase IIb eteplirsen study, presented the full set of 48-week data from…
Added by PPMD on October 16, 2012 at 9:00am — No Comments
Latest Blog Posts
- Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
- Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne
- Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
- Roche Restarts RG62026 Phase 2/3 Study
- [WEBINAR] What is a Master Protocol?
- Santhera Shares Duchenne Community Update on SIDEROS Trial
- Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
Most Popular Blog Posts
- April 25: FDA Advisory Committee Meeting for Eteplirsen - Live Webcast Information
- September 28: FDA Advisory Committee Meeting for Ataluren - Live Webcast Information
- Action ALERT: Urge Congress to Vote YES on 21st Century Cures Act
- Summit Receives Fast Track Designation from FDA for Ezutromid in the Treatment of Duchenne
- Ongoing Traumatic Stress
- PTC Therapeutics to Discuss Launch Plans for Emflaza™ (Deflazacort) during Community Call on Monday, May 8th at 3:00 PM EDT
- Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 & SRP-4053
Monthly Archives
2018
2017
- December (11)
- November (8)
- October (7)
- September (10)
- August (2)
- July (1)
- June (7)
- May (5)
- April (8)
- March (9)
- February (6)
- January (7)
2016
- December (5)
- November (4)
- October (11)
- September (7)
- August (5)
- July (7)
- June (5)
- May (3)
- April (10)
- March (7)
- February (5)
- January (9)
2015
- December (16)
- November (5)
- October (7)
- September (4)
- August (5)
- July (10)
- June (6)
- May (4)
- April (2)
- March (4)
- February (5)
- January (3)
2014
- December (5)
- November (3)
- October (5)
- September (3)
- August (2)
- July (9)
- June (6)
- May (7)
- April (40)
- March (17)
- February (2)
- January (3)
2013
- December (19)
- November (52)
- October (1)
- September (4)
- August (3)
- July (1)
- June (4)
- May (4)
- April (7)
- March (8)
- February (5)
- January (3)
2012
- December (3)
- November (2)
- October (4)
- September (2)
- August (1)
- July (1)
- June (1)
- May (2)
- April (1)
- March (4)
- February (8)
- January (1)
2011
2010
© 2022 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
